Immunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant Melanoma

Tefany, Frances J.; Barnetson, Ross StC; Halliday, Gary M.; McCarthy, Stanley W.; McCarthy, William H.

doi:10.1111/1523-1747.ep12479662

Cited by 146 publications

(83 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As in our study, tumour-infiltrating T lymphocytes (TILs) have been found in increasing numbers in regressing primary melanoma. 44 Adoptive transfer of melanoma TILs have resulted in tumour remissions in patients with metastatic melanoma, 45,46 as has vaccine therapy aimed at inducing CTLs to melanoma TAAs. 47 These results are consistent with the finding in animal model systems that tumourspecific T-cell TILs are 50 -100 times more potent than lymphokine-activated killer cells in mediating tumour regression in vivo.…”

Section: Discussionmentioning

confidence: 99%

Primary melanoma tumour regression associated with an immune response to the tumour‐associated antigen melan‐A/MART‐1

et al. 2001

View full text Add to dashboard Cite

A prediction of the theory of immunologic surveillance is that tumour antigens can be recognised by cell-mediated immunity during early development of the primary tumour by formation of tumour antigen-specific cytotoxic lymphocytes (CTLs) and that such recognition leads to destruction of those tumour cells (tumour regression) with subsequent appearance of tumour antigen-loss variants. However, this has never been shown in nonviral-induced experimental animal models of primary malignancy or in human primary cancer. We examined 2 groups of human melanoma patients where primary tumour regression was observed. Twentythree patients with multiple (>3) primary melanoma showed significant histologic regression of their last tumour (median tumour regression 33%) compared to matched tumours from patients with a single primary melanoma (median 0%) (p ‫؍‬ 0.008) or compared to their first primary tumour (median 0%) (p ‫؍‬ 0.001). This increased regression is consistent with an "immunisation effect" seen in murine tumour transplantation studies where innoculation with >3 asynchronous tumours induces transplantation rejection on subsequent challenge. A significant decrease in MART-1-positive stained tumour area in the last primary tumour from multiple melanoma subjects (median 8%) vs. matched single melanoma patients (median 79%) (p ‫؍‬ 0.004) and in the last vs. first tumour (median 76%) in multiple primary subjects was found (p ‫؍‬ 0.008). Metastatic tumours from 17 patients whose primary skin melanomas had completely regressed (occult primary melanoma) also showed significant MART-1 tumour-loss variants (median 0% MART-1-positive tumour) compared to matched metastatic tumours from patients with nonregressing primary tumours (median 51%) (p ‫؍‬ 0.001). A correlation with the presence of peripheral blood MART-1-specific CTLs (MHC class I-restricted IFN-␥ producing T lymphocytes) and MART-1 tumour antigen-loss variants was found (p ‫؍‬ 0.001). Thus, in 2 groups of human melanoma subjects, we provide evidence of tumour regression associated with Melan A/MART-1 tumour antigen-loss variants correlating with formation of specific Melan A/MART-1 CTLs.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary melanoma tumour regression associated with an immune response to the tumour‐associated antigen melan‐A/MART‐1

et al. 2001

View full text Add to dashboard Cite

show abstract

“…( [19], p. 141). A preceding staging workup also follows applicable standards for stage III and IV melanoma [451][452][453]. "Melanoma is among a number of cancers in humans where the primary tumour cannot always be found.…”

Section: S Reskementioning

confidence: 99%

“…In some patients the primary may be in an obscure site such as the eye, ear or the intestine, but in the majority it is likely that the primary tumour has been destroyed by the host's immune system via lymphocyte activation. [451,453]. It is likely that total regression occurs in 10-20% of melanomas, though only those where there have been metastases are diagnosable (about 5 % of melanomas)."…”

Section: S Reskementioning

confidence: 99%

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Pflugfelder

Kochs

Blum

et al. 2013

J Deutsche Derma Gesell

180

148

View full text Add to dashboard Cite

“…A regressão espontânea representa a resposta imunológica do hospedeiro contra a neoplasia (8,29,31,34,36) . A partir desse conceito, seria coerente esperar melhor evolução nos pacientes que apresentam tal reação.…”

Section: Regressão Como Fator Prognósticounclassified

Estudo da espessura da regressão como fator prognóstico nos melanomas cutâneos finos

Pantaleão¹,

Rochael²

2008

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

Introdução: O diagnóstico de melanomas cutâneos finos (MCF) é cada vez mais freqüente. Essas lesões, inicialmente associadas a excelente prognóstico, têm apresentado recidiva ou metástases e, às vezes, óbito. Muitas variáveis têm sido estudadas e, embora nenhuma delas tenha esclarecido tal comportamento, a regressão e seu possível impacto negativo têm merecido atenção. A regressão tardia é referida pelos autores como de maior relevância no prognóstico. Objetivo: Correlacionar a espessura máxima da área de regressão dos MCFs com o tempo de sobrevida livre de doença.

show abstract

Immunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant Melanoma

Cited by 146 publications

References 27 publications

Primary melanoma tumour regression associated with an immune response to the tumour‐associated antigen melan‐A/MART‐1

Primary melanoma tumour regression associated with an immune response to the tumour‐associated antigen melan‐A/MART‐1

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

Estudo da espessura da regressão como fator prognóstico nos melanomas cutâneos finos

Contact Info

Product

Resources

About